To assess the efficacy and safety of AKBA ULTRAâ?¢ in the management of clinical symptoms of osteoarthritis.
- Conditions
- Health Condition 1: M179- Osteoarthritis of knee, unspecified
- Registration Number
- CTRI/2019/03/018264
- Lead Sponsor
- Ambe Phytoextracts Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients with osteoarthritis of the knee joints X ray screened, with no other known rheumatological condition and who report the following clinical features based on the ACR classification for knee OA.
-knee pain on most days of the previous month, -morning stiffness of less than thirty minutes duration
-stiffness in resting the joint.
2.Patients who have been on stable medication conventional or complementary, including nutritional medicine for the past three months, but are still getting symptoms incomplete responders.
3.Patients with visual analog scale VAS score that assessed pain during the most painful knee movement had to be more than forty.
4.Patients able to walk and give both verbal and written information regarding the study.
5.Willing to give written informed consent.
6.Patients willing to and able to comply with all trial requirements.
7.Patients who have not participated in a similar investigation in the past four weeks.
8.Female patients with negative UPT.
9.Female patients with child bearing potential must be willing to agree to use effective contraceptive methods while on treatment and for three months after the completion of study.
10. Male and female Volunteers, with age between 40to70 years
11.Patients with functional index more than seven points.
1. Patients with clinical evidence or known history of severe cardiac, pulmonary, gastrointestinal, renal, hepatic or neurological disorders
2. History of allergy to aspirin or NSAIDs.
3. Patients who have undergone total knee replacement in the contralateral knee within 6 months prior to the screening visit.
4. Patients who have received an intra articular corticosteroid injection in a lower joint during the three months prior to the baseline visit.
5. Patients with isolated lateral compartment disease defined by joint space loss in the lateral compartment only.
6. Patients who have received chondrocyte transplants in any lower extremity joint.
7. Patients with comorbid conditions that restrict knee function.
8. Patients taking treatment with corticosteroids within last 3 months.
9. Patient with infectious arthritis or gout or underlying inflammatory arthropathy or hyperuricemia
10. Patients with recent injury in the area affected by OA of the knee.
11. Patients with abnormal liver or kidney function tests, major abnormal finding on complete blood count, history of coagulopathies, hyperkalemia, pregnancy, lactation
12. Patients with history of peptic ulceration and upper GI hemorrhage
13. Patients with uncontrolled hypertension, congestive heart failure
14. Patients with prior diagnosed malignant tumours
15. Patients having allergy or sensitivity to study drugs and excipients in the formulation.
16. .Participating in a clinical research trial within 30 days prior to screening.
17. Any other health or mental condition that in the Investigatorâ??s opinion may adversely affect the patientâ??s ability to complete the study or its measures or that may pose significant risk to the patient.
18. Female patients who are pregnant, breast feeding, nursing or planning to become pregnant during study participation or did not agree to use an acceptable form of birth control throughout the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method